 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/7670
Post Genome Project Era Proteomics R&D Competition
|
Description: |
Proteomics is projected to grow from a $565 million market in 2001 to over $3.3 billion in 2006. This represents an average annual rate of growth of over 40%. The fastest growing segment of the proteomics market is expected to be the protein chip segment that will increase from $65.7 million in 2001 to over $723 million in 2006. This represents a 11-fold increase in market size in a six-year period and an average annual growth rate approaching 62%. Demand for proteomics services is expected to be strong throughout this time period with an average annual growth rate of over 50%. The rate of growth in this market segment is expected to slow after 2004 when next generation proteomics platforms are introduced. The proteomics platform market segment will remain the largest with a growth from $311 million in 2001 to approximately $1.7 billion in 2006.
Following the release of the first full draft of the human genome, the spotlight in biomedical research is shifting from genomics to proteomics as the key technology to transform information into pharmaceutical products. The need to improve the speed and efficiency of drug discovery is the primary driver of proteomics. Current step-wise screening and chemical optimization methods are both time-consuming (averaging 10-12 years from discovery to market) and expensive (estimated costs range from $500M-$750M). In addition, there is a high rate of failure in the clinical trials process due to toxicity or low efficacy of selected drug targets resulting in an increased interest in identification of biomarkers suitable to use in therapeutic planning and individualized medicine. It is hoped that both the rate of drug development and the rate of discovery of novel, informative biomarkers will dramatically improve using emerging proteomics platforms.
The use of proteomics capabilities has the potential to decrease overall spending per new chemical compound by approximately 30%, while decreasing the time investment by two years. The reality is that genomic technologies (use of DNA arrays and mRNA profiling) have resulted in a bottleneck in target validation. In order to realize the potential for efficiency, both genomics and proteomics need to be leveraged by applying these tools throughout validation to result in suitable and validated targets. This will require the construction of a systems biology framework to understand on a molecular level the disease mechanisms that often involve multiple targets and pathways.
All major pharmaceutical companies are searching for ways of accelerating drug discoveries. An important strategy to increase efficiency and reduce attrition in discovery is the ability to develop new drugs in parallel with disease biomarkers. With decreasing numbers of drugs in the clinical pipeline, Pharma (the pharmaceutical industry) is actively evaluating methods to increase the return on their R&D dollars by raising R&D productivity. Proteomics offers a clearer path toward this than genomics for several reasons. First, the same proteomics platforms can be used to test multiple biochemical properties. When the same target screen positive in multiple tests, it increases confidence in the role of that target in the disease of interest. Second, proteomics targets the biomolecules responsible for disease directly while genomics measures the levels of the messages encoding them, an indirect measurement of correlation. Third, proteomics platforms that are used in R&D for discovering drug targets can also be used in upstream in both pre-clinical R&D and post-clinical development. For example, the same tests on proteomic chips are being applied to in drug discovery, target validation, biomarker studies and drug candidate evaluation. Similarly, the hybrid sample preparation/MS analysis platforms under active development by several proteomics platform providers can be used both in discovery and in screening all the way through manufacturing QC to test product purity. |
|
Contents: |
1. Executive Overview
2. The Market Overview For Proteomics In Pharmaceutical R&D
Definition Of Proteomics Market
Recent Industry Trends That Impact Proteomics Market
3. Current Proteomics Market Participants By Market Segment
Technologies Used In Proteomics
Emerging Proteomics Technologies
Proteomics Chip Providers
Proteomics Platform Providers
Reagent or Antibody Providers
Proteomics Informatics Tools and Database Providers
Proteomic Service Providers
Proteomics-based Drug Discovery Companies
The Drug Development Process
4. Drivers Of Proteomics Market
Pharmaceutical Drug Discovery R&D
Japan To Play Key Role In 'Golden Age Of Discovery
Genomics Contribution To Drug Development
Need For Systems Approach To Biological Research
Limitations of DNA Chips and Expression Profiling
Technical Challenges With Protein Chips
Post Human Genome Project Era Proteomics Databases
5. Case Studies In Proteomic Platforms For Pharmaceutical R&D
Collaborative Landscape In Proteomics: Strategic Alliances And Partnerships
Strategic Alliances In The Proteomics Market Segments
Alliances with Platform Providers
Alliances with Proteomics Arrays or Protein Chips
Alliances with Informatics and Database Providers
Alliances with Proteomic Reagent Providers
Alliances with Proteomic Service Providers
Recent Key Strategic Alliances And Partnerships
Applied Biosystems & HTS Biosystems: An R&D and marketing collaboration
Bruker Daltonics & Roche: Platform development collaboration
Celera & SomaLogic: Technology access collaboration
Ciphergen & Beckman Coulter: Robotic upgrade to leading platform
Correlogic & Ciphergen: Diagnostic discovery collaboration
Gyros & Affibody: Technology development strategic alliance
MDS Proteomics & Thermo Finnigan: Platform development collaboration
NeoGenesis & Mass General Hospital: Clinical collaboration
Phylos & Upstate: Reagent development collaboration
Large Scale Biology & NIEHS: Academic research collaboration
Oxford GlycoSciences & BioInvent: Drug-discovery collaboration
Proteome Systems & Itochu: An international joint venture
6. Drug Discovery Pipeline Engaging Proteomics
7. Future Outlook For Proteomics Market
Forecast For Proteomics By Market Segments
Platform Provider Market Segment
Protein Chip Provider Segment
Informatics Provider Market Segment
Reagent Provider Market Segment
Services Provider Market Segment
Comparison of the Market Segment Forecasts
Proteomics Market Size by Segment, 2002~2006
Total Size Of The Proteomics Market
8. Future Directions In Proteomics
Overview Of Past Trends
Recent Developments In Genomics That Impact Proteomics
Indicators Of Future Trends In Proteomics
9. Company Profiles
Protein Chip Providers
Aspira Biosystems
BioForce Nanosciences
Biosite Discovery
Glaucus Proteomics
Milagen, Inc.
Phylos
Protometrix
Platform Providers
20/20 GeneSystems, Inc
Agilent Technologies
Applied Biosystems
Biacore AB
Ciphergen
CombiMatrix
HTS Biosystems
Kinexus
Large Scale Biology
Perkin-Elmer, Inc.
Prolinx
Proteome Systems Ltd.
Randox
SomaLogic
Zeptosens
Zyomyx, Inc.
Reagent Providers
Bioinvent
Cambridge Antibody Technology
LYNX
Upstate
Services Providers
Affinium Pharmaceuticals
GeneProt
Protagen AG
Syrrx
Informatics And Database Providers
AxCell Biosciences
Compugen
GeneFormatics
InforMax
Iconix Pharmaceuticals
LabVantage Solutions
Matrix Science
Nonlinear Dynamics
ProteoMetrics
Proteomics-Based Drug Discovery Companies
ACE BioSciences
Archemix
Beyond Genomics
Celera Genomics
MDS Proteomics, Inc.
NeoGenesis Pharmaceuticals, Inc.
Oxford GlycoSciences
10. Lessons Learned And Emerging Opportunities
Genomics Companies Restructure And Focus On Proteomics
Challenges Of Drug Discovery R&D Process
Next Hot Development Areas In Proteomics
Proteomics Opportunities
Role In Drug Discovery
Role in Toxicology and Toxicogenomics
Role in Basic Research
Large-Scale Proteomics Takes Off
11.Summary
Appendix A - Listing Of Proteomics Vendors
Appendix B - Proteomics Glossary
2D-gel electrophoresis
activity based proteomics
antibody chips
carbohydrate chips
cell chips/ microarrays
cell-based drug discovery
cellular proteome
chemical chips/ microarrays
chemical genetics
chemical proteomics
computational proteomics
compound validation
functional proteomics
functional protein arrays
high-throughput proteomics
Human Proteome Organization (HUPO)
Human Proteomics Initiative in silico proteomics
medicinal chemistry
physiological proteomics
protein-DNA interaction methods
protein chips
proteomics
structural chemogenomics
suspension arrays
tissue biochips/microarrays
toxicogenomics |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/7670
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 02/12/2008 01:56:20 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Post Genome Project Era Proteomics R&D Competition
|
|
Web Address: |
http://www.researchandmarkets.com/reports/7670
|
|
Office Code: |
|
OCIFGKJSTUS
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Hard Copy
|
|
€1,187.00 + EUR€ 50.00 Shipping/Handling *
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
Page 2 of 2
Printed 02/12/2008 01:56:20
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder Name: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
|
|
|
|
